Programs
Description
Discovery
Pre-Clinical
IND
Phase 1
PHASE 2
GM-1020: Oral NMDAR Antagonist
Orally Bioavailable, Rapid-acting, Fewer Dissociative Effects, Indications: Depression and Others
Non-hallucinogenic, Abuse-deterrent, Improved Cardiac Safety Profile, Indications: Depression and Others
Improved Cardiac Safety Profile, Improved Efficacy, Indications: Opioid Abuse Disorder and others
Rapid-acting, Cost-effective, Improved Cardiac Safety Profile, Indications: Depression and Others
GM-200X: 5-HT2AR Non-Pyschoactive
GM-2505: 5-HT2A Agonist/5-HT Releaser
GM-300X: Safer Ibogaine Analogs
Program
GM-1020: Oral NMDAR Antagonist
Description
Orally Bioavailable, Rapid-acting, Fewer Dissociative Effects, Indications: Depression and Others
Phase
Discovery | Pre-Clinical | IND | Phase 1
Program
GM-2505: 5-HT2AR Short Acting Reset
Description
Rapid-acting, Cost-effective, Improved Cardiac Safety Profile, Indications: Depression and Others
Phase
Discovery | Pre-Clinical | IND | Phase 1
Program
GM-200X: 5-HT2AR Non-Hallucinogenic
Description
Orally Bioavailable, Rapid-acting, Fewer Dissociative Effects, Indications: Depression and Others
Phase
Discovery | Pre-Clinical | IND | Phase 1
Program
GM-300X: Safer Ibogaine Analogs
Description
Improved Cardiac Safety Profile, Improved Efficacy, Indications: Opioid Abuse Disorder and others
Phase
Discovery | Pre-Clinical | IND | Phase 1
